<?xml version="1.0" encoding="UTF-8"?>
<ref id="B139-viruses-12-01039">
 <label>139.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Cao</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Wei</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Zou</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Jiang</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Meng</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>N.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial</article-title>
  <source>J. Allergy Clin. Immunol.</source>
  <year>2020</year>
  <volume>146</volume>
  <fpage>137</fpage>
  <lpage>146</lpage>
  <pub-id pub-id-type="doi">10.1016/j.jaci.2020.05.019</pub-id>
  <pub-id pub-id-type="pmid">32470486</pub-id>
 </element-citation>
</ref>
